Green Cross Medical Science Corporation Total Liabilities
Green Cross Medical Science Corporation total liabilities. Based on the latest financial reports, Green Cross Medical Science Corporation (142280) has total liabilities worth ₩40.86 Billion KRW (≈ $27.69 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 142280 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Green Cross Medical Science Corporation (2014–2025)
Total liabilities of Green Cross Medical Science Corporation from 2014 to 2025. This chart illustrates how Green Cross Medical Science Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore 142280 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Green Cross Medical Science Corporation Competitors by Total Liabilities
The table below lists competitors of Green Cross Medical Science Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brand Group (M.G) Ltd
TA:BRND
|
Israel | ILA615.29 Million |
|
Aureus Greenway Holdings Inc.
NASDAQ:PUSA
|
USA | $1.54 Million |
|
OS Therapies Incorporated
NYSE MKT:OSTX
|
USA | $4.25 Million |
|
Mondi PLC
LSE:MNDI
|
UK | GBX5.03 Billion |
|
Mobileleader Co.Ltd
KQ:100030
|
Korea | ₩23.52 Billion |
|
Oceanpal Inc
NASDAQ:OP
|
USA | $4.10 Million |
|
Australian Vanadium Ltd
AU:AVL
|
Australia | AU$13.62 Million |
|
Adaptimmune Therapeutics plc
F:473A
|
Germany | €201.59 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Green Cross Medical Science Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Green Cross Medical Science Corporation total assets.
Liquidity & Leverage Metrics
Green Cross Medical Science Corporation Total Liabilities Ratios Explained
Green Cross Medical Science Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Green Cross Medical Science Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Green Cross Medical Science Corporation (2014–2025)
The table below shows the annual total liabilities of Green Cross Medical Science Corporation from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩44.14 Billion ≈ $29.92 Million |
-5.59% |
| 2024-12-31 | ₩46.76 Billion ≈ $31.69 Million |
-12.77% |
| 2023-12-31 | ₩53.61 Billion ≈ $36.33 Million |
-15.20% |
| 2022-12-31 | ₩63.22 Billion ≈ $42.84 Million |
+6.22% |
| 2021-12-31 | ₩59.51 Billion ≈ $40.33 Million |
+21.12% |
| 2020-12-31 | ₩49.14 Billion ≈ $33.30 Million |
+25.06% |
| 2019-12-31 | ₩39.29 Billion ≈ $26.63 Million |
-19.21% |
| 2018-12-31 | ₩48.63 Billion ≈ $32.96 Million |
+30.35% |
| 2017-12-31 | ₩37.31 Billion ≈ $25.28 Million |
+1.50% |
| 2016-12-31 | ₩36.76 Billion ≈ $24.91 Million |
-15.97% |
| 2015-12-31 | ₩43.74 Billion ≈ $29.64 Million |
+112.38% |
| 2014-12-31 | ₩20.60 Billion ≈ $13.96 Million |
-- |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more